These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 305674)

  • 1. Thymosin treatment of children with primary immunodeficiency disease.
    Wara DW; Ammann AJ
    Transplant Proc; 1978 Mar; 10(1):203-9. PubMed ID: 305674
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro and in vivo enhancement of mixed lymphocyte culture reactivity by thymosin in patients with primary immunodeficiency disease.
    Wara DW; Barrett DJ; Ammann AJ; Cowan MJ
    Ann N Y Acad Sci; 1979; 332():128-34. PubMed ID: 161150
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunologic reconstitution of patients with primary immunodeficiency diseases and cancer after treatment with thymosin.
    Goldstein AL; Thurman GB; Rossio JL; Costanzi JJ
    Transplant Proc; 1977 Mar; 9(1):1141-4. PubMed ID: 325742
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
    Levinsky RJ; Davies EG; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):273-6. PubMed ID: 6360239
    [No Abstract]   [Full Text] [Related]  

  • 5. Experiences with thymosin in primary immunodeficiency disease.
    Astaldi A; Astaldi GC; Wijermans P; Dagna-Bricarelli F; Kater L; Stoop JW; Vossen JM
    Cancer Treat Rep; 1978 Nov; 62(11):1779-85. PubMed ID: 215306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymosin for immunodeficiency diseases and cancer.
    Goldstein AL; Rossio JL
    Compr Ther; 1978 Feb; 4(2):49-57. PubMed ID: 624213
    [No Abstract]   [Full Text] [Related]  

  • 7. [Regular trisomy 21 and combined immunodeficiency. Ineffectiveness of thymosin].
    Calvani M; Aiuti F; Felici N; D'Amelio R; Picchio E
    Minerva Pediatr; 1979 Dec; 31(23):1691-7. PubMed ID: 162325
    [No Abstract]   [Full Text] [Related]  

  • 8. The thymus in immunodeficiency diseases: new therapeutic approaches.
    Bach JF
    Birth Defects Orig Artic Ser; 1983; 19(3):245-53. PubMed ID: 6360235
    [No Abstract]   [Full Text] [Related]  

  • 9. Thymosin: basic properties and clinical potential in the treatment of patients with immunodeficiency diseases and cancer.
    Goldstein AL
    Antibiot Chemother (1971); 1978; 24():47-59. PubMed ID: 350140
    [No Abstract]   [Full Text] [Related]  

  • 10. Thymopoietin pentapeptide treatment of primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Rossi P; Seminara R; Goldstein G
    Lancet; 1983 Mar; 1(8324):551-4. PubMed ID: 6131256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosette-forming cells, immunologic deficiency diseases and transfer factor.
    Wybran J; Levin AS; Spitler LE; Fudenberg HH
    N Engl J Med; 1973 Apr; 288(14):710-3. PubMed ID: 4540063
    [No Abstract]   [Full Text] [Related]  

  • 13. [Genetic aspects of immunologic deficiency syndromes].
    Geiger H
    Verh Dtsch Ges Inn Med; 1974; 80():1007-15. PubMed ID: 4616483
    [No Abstract]   [Full Text] [Related]  

  • 14. Thymic function in man.
    Pahwa R; Ikehara S; Pahwa SG; Good RA
    Thymus; 1979 Sep; 1(1-2):27-58. PubMed ID: 317931
    [No Abstract]   [Full Text] [Related]  

  • 15. The Gordon Wilson lecture. The history of the development of thymosin: chemistry, biology and clinical applications.
    Goldstein AL
    Trans Am Clin Climatol Assoc; 1977; 88():79-94. PubMed ID: 331647
    [No Abstract]   [Full Text] [Related]  

  • 16. Demonstration of abnormalities in expression of thymic epithelial surface antigens in severe cellular immunodeficiency diseases.
    Haynes BF; Warren RW; Buckley RH; McClure JE; Goldstein AL; Henderson FW; Hensley LL; Eisenbarth GS
    J Immunol; 1983 Mar; 130(3):1182-8. PubMed ID: 6600476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human thymus lymphoid tissue (HTL) antigen, complement receptor and rosette formation with sheep erythrocytes of the lymphocytes from primary immunodeficiency diseases.
    Yata J; Tsukimoto I; Arimoto T; Goya N; Tachibana T
    Clin Exp Immunol; 1973 Jul; 14(3):309-17. PubMed ID: 4579777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Personal experiences of immunotherapy using the transfer factor].
    D'Amelio R; Franchi F; Aiuti F
    Minerva Med; 1976 May; 67(24):1613-6. PubMed ID: 934516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The primary immunodeficiency diseases: classification, pathogenesis and treatment.
    Gatti RA; Seligmann M
    Turk J Pediatr; 1973 Oct; 15(4):195-215. PubMed ID: 4600502
    [No Abstract]   [Full Text] [Related]  

  • 20. The pathogenesis and treatment of immunodeficiency.
    Horowitz SD; Hong R
    Monogr Allergy; 1977; 10():1-198. PubMed ID: 327292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.